Identifying Macromolecules (PDF)

Raman spectroscopy just got a brain, a stopwatch, and a nose. Together, these upgrades are turning a century-old light-scattering trick into a frontline tool for catching cancer earlier, chiral drugs cleaner, and toxic chemicals faster than ever before.

At the upcoming 2026 SciX Conference, Ji-Xin Cheng at Boston University will be recognized with the Charles Mann Award for Applied Raman Spectroscopy. Leading up to the conference, Cheng sat down with Spectroscopy to talk about the advancements being made in confocal Raman microscopy.

Raman microspectroscopy can be used to characterize polycyclic aromatic hydrocarbons. Pavi Sundararajan, a postdoctoral fellow at NASA Ames Research Center, explains how.

The following articles are the most accessed digital object identifier (DOI) manuscripts for Spectroscopy and LCGC International during the month of August 2026. Ten articles are individually ranked here by DOI page views.

An upcoming talk at SciX 2026 Conference will describe a new multimodal platform using laser ablation inductively coupled plasma–mass spectrometry (LA-ICP-MS) elemental mapping that can detect nanoparticles and microplastics in biological tissue.

An upcoming interview with Ji-Xin Cheng, a Theodore Moustakas Distinguished Professor in Photonics and Optoelectronics at Boston University, will highlight his ongoing work in coherent Raman scattering microscopy.

Reliability, dynamic measurements, artificial intelligence, and real-world applications are reshaping Raman spectroscopy – while Molecular Photonics points toward new translational frontiers.

Jurgen Popp, Thomas Mayerhofer, and colleagues at Leibniz IPHT and Friedrich Schiller University Jena introduce the Personalized Optical Digital Twin (PODT), a Photonics21 contribution to Europe's Virtual Human Twin ecosystem that connects molecular photonics—Raman blood analysis, coherent Raman tissue imaging, and multimodal endomicroscopy—with longitudinal physiology and clinical data. Drawing on the published multicenter INTELLIGENCE trials, the authors argue that technical feasibility and clinical utility must be evaluated separately as the field moves toward Europe's FP10 research agenda.